Found: 39
Select item for more details and to access through your institution.
Letter: choosing between ustekinumab and vedolizumab in anti‐TNF refractory Crohn's disease—the devil is in the detail.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 561, doi. 10.1111/apt.15862
- By:
- Publication type:
- Article
Editorial: which factors influence HBsAg levels in HBV‐infected patients? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 549, doi. 10.1111/apt.15910
- By:
- Publication type:
- Article
Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis? Author's reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 546, doi. 10.1111/apt.15866
- By:
- Publication type:
- Article
Editorial: which factors influence HBsAg levels in HBV‐infected patients?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 547, doi. 10.1111/apt.15864
- By:
- Publication type:
- Article
Letter: faecal microbiota transplantation for IBS.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 556, doi. 10.1111/apt.15824
- By:
- Publication type:
- Article
Editorial: balancing safety and efficacy—6‐TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 554, doi. 10.1111/apt.15922
- By:
- Publication type:
- Article
Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 568, doi. 10.1111/apt.15919
- By:
- Publication type:
- Article
Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 527, doi. 10.1111/apt.15915
- By:
- Publication type:
- Article
Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 449, doi. 10.1111/apt.15834
- By:
- Publication type:
- Article
Letter: early TIPSS in acute variceal bleed—debate continues.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 579, doi. 10.1111/apt.15909
- By:
- Publication type:
- Article
Review article: chronic liver disease and pregnancy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 420, doi. 10.1111/apt.15908
- By:
- Publication type:
- Article
Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 430, doi. 10.1111/apt.15907
- By:
- Publication type:
- Article
Editorial: early TIPSS in patients with cirrhosis and acute variceal bleeding—the plot thickens!
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 551, doi. 10.1111/apt.15904
- By:
- Publication type:
- Article
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 500, doi. 10.1111/apt.15901
- By:
- Publication type:
- Article
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 560, doi. 10.1111/apt.15899
- By:
- Publication type:
- Article
Letter: ciclosporin and vedolizumab for steroid‐refractory ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 578, doi. 10.1111/apt.15896
- By:
- Publication type:
- Article
Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID‐19.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 577, doi. 10.1111/apt.15895
- By:
- Publication type:
- Article
Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 571, doi. 10.1111/apt.15893
- By:
- Publication type:
- Article
Letter: ustekinumab dose intensification for loss of response—should we re‐induce before shortening the dose interval? Author's reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 565, doi. 10.1111/apt.15892
- By:
- Publication type:
- Article
Letter: combination of biologics in inflammatory bowel diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 566, doi. 10.1111/apt.15891
- By:
- Publication type:
- Article
Letter: choosing between ustekinumab and vedolizumab in anti‐TNF refractory Crohn's disease—the devil is in the detail. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 563, doi. 10.1111/apt.15888
- By:
- Publication type:
- Article
Letter: liver disease and COVID‐19—not the perfect storm. Authors' reply".
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 574, doi. 10.1111/apt.15886
- By:
- Publication type:
- Article
Quality improvement project identifies factors associated with delay in IBD diagnosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 471, doi. 10.1111/apt.15885
- By:
- Publication type:
- Article
Duration of adhesion of swallowed alginates to distal oesophageal mucosa: implications for topical therapy of oesophageal diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 442, doi. 10.1111/apt.15884
- By:
- Publication type:
- Article
Letter: ustekinumab dose intensification for loss of response—should we re‐induce before shortening the dose interval?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 564, doi. 10.1111/apt.15883
- By:
- Publication type:
- Article
MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 492, doi. 10.1111/apt.15882
- By:
- Publication type:
- Article
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 576, doi. 10.1111/apt.15881
- By:
- Publication type:
- Article
Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 537, doi. 10.1111/apt.15880
- By:
- Publication type:
- Article
Editorial: pancreatic cancer risk in inflammatory bowel diseases—it's all relative.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 550, doi. 10.1111/apt.15877
- By:
- Publication type:
- Article
No benefit of continuing vs stopping 5‐aminosalicylates in patients with ulcerative colitis escalated to anti‐metabolite therapy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 481, doi. 10.1111/apt.15876
- By:
- Publication type:
- Article
Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 557, doi. 10.1111/apt.15875
- By:
- Publication type:
- Article
Letter: liver disease and COVID‐19—not the perfect storm.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 572, doi. 10.1111/apt.15872
- By:
- Publication type:
- Article
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 575, doi. 10.1111/apt.15829
- By:
- Publication type:
- Article
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 559, doi. 10.1111/apt.15828
- By:
- Publication type:
- Article
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 513, doi. 10.1111/apt.15830
- By:
- Publication type:
- Article
Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 569, doi. 10.1111/apt.15814
- By:
- Publication type:
- Article
Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 545, doi. 10.1111/apt.15792
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 417, doi. 10.1111/apt.15351
- Publication type:
- Article
Adjustment of azathioprine dose should be based on a lower 6‐TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 52, n. 3, p. 459, doi. 10.1111/apt.15810
- By:
- Publication type:
- Article